恒瑞醫(yī)藥（股票代碼600276）是一家以生產(chǎn)和銷售抗腫瘤藥、手術用藥、心血管及內(nèi)分泌藥物為主的創(chuàng)新型制藥企業(yè)，國家定點麻醉藥品生產(chǎn)廠家。2000年在滬市上市，2010年在醫(yī)藥上市企業(yè)Zui具競爭力二評選中，公司名列第一，股票市值位列A股醫(yī)藥上市企業(yè)前三名。 公司建有企業(yè)技術中心，博士后科研工作站，是國家重點高新技術企業(yè)，國家“863”計劃成果產(chǎn)業(yè)化基地，國家火炬計劃新醫(yī)藥研究開發(fā)及產(chǎn)業(yè)化基地的骨干企業(yè)之一。 恒瑞醫(yī)藥是國內(nèi)Zui大的抗腫瘤藥物研究和生產(chǎn)基地，先后打造了艾恒、艾素、艾力等眾多知名品牌，市場份額在國內(nèi)排名第一；此外，公司生產(chǎn)的手術用藥、消化道用藥所占市場份額居國內(nèi)行業(yè)前列。2008年，國家科技部組織實施“重大新藥創(chuàng)制”專項，恒瑞醫(yī)藥以企業(yè)第一名的評分率先入選重大專項新藥孵化器基地。2010年被科技部評定為“中國抗腫瘤藥物技術創(chuàng)新產(chǎn)學研聯(lián)盟”的牽頭單位。2010年被國家工信部評為國內(nèi)研發(fā)產(chǎn)品線十佳第一名。2009年8月，公司自主研發(fā)的用于治療Ⅱ糖尿病的一類新藥瑞格列汀在美國獲批進入一期臨床，這是我國化學制藥行業(yè)首次在美國進行創(chuàng)新藥的臨床試驗，下一步公司還將向美國申請抗腫瘤創(chuàng)新藥進行臨床實驗。 恒心致遠，瑞頤人生。恒瑞人一直秉承“為人類創(chuàng)造健康生活”的理念，為鑄就百年恒瑞而不斷努力奮斗。 恒瑞醫(yī)藥在美國、上海和連云港、成都均設立研究中心，并在北京設立臨床醫(yī)學部，擁有各類高層次研發(fā)人員700多名，其中有400名博士、碩士及海歸人士。Jiangsu Hengrui Medicine is a fully integrated pharmaceutical company with R & D, manufacturing, and sales of oncology, CV, anti-infective, surgical drugs and contrast media.State Designated Manufacturer of Narcotic Drugs .Hengrui Medicine has Listed in Shanghai Securities Exchange in 2000; In 2010, ranked first among 20 of the most competitive public companies in the pharma sector in China; Ranked as top three in the stock market value of A Gu of Chinese public pharmaceutical companies.Designated head liaison by Ministry of Chinese Science and Technology for the China Research Alliance of Innovation in Anti-neoplastic Drugs.Hengrui Medicine has two state-of-art R&D centers in Shanghai and Lianyungang. Its medical department is located in Shanghai. In addition, there are four oversee R&D facilities in US and Sweden. Currently over 600 scientists are employed, including 150 PhD, MS, and oversee returnees. Retgliptin, a DPP-4 inhibitor, was tested in Phase 1 in the US in August, 2009. This was the first entry of an NME created by a Chinese pharmaceutical company in the US for clinical evaluation. A series of NMEs in the area of oncology& diabetes are being prepared for clinicaltests on a global scale.A fully integrated, globally-competitive pharmaceutical company capable of delivering 1-2 NMEs annually to patients with unmet medical needs.